Inhibition of the c-Myc Oncogene by the Aureolic Acid Group Antibiotics.
antitumor antibiotics
c-Myc oncogene
low molecular weight chemical compounds
olivomycin A
transcription
Journal
Doklady. Biochemistry and biophysics
ISSN: 1608-3091
Titre abrégé: Dokl Biochem Biophys
Pays: United States
ID NLM: 101126895
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
27
04
2021
accepted:
07
05
2021
revised:
06
05
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
5
2
2022
Statut:
ppublish
Résumé
GC-rich stretches in the DNA minor groove are the established intracellular targets for the aureolic acid group of antibiotics such as olivomycin A and its semisynthetic analogue olivamide. We demonstrated here that both antibiotics at nanomolar concentrations inhibited transcription of the c-Myc oncogene in cultured human tumor cells. The mechanism of transcriptional inhibition did not require the full-length binding site for Sp1, a GC-dependent transcriptional factor. GC quartets with the nucleotide sequences optimal for drug binding are sufficient for c-Myc transcriptional block by the aureolic acid derivatives.
Identifiants
pubmed: 34697733
doi: 10.1134/S1607672921050094
pii: 10.1134/S1607672921050094
doi:
Substances chimiques
Plicamycin
NIJ123W41V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
308-311Informations de copyright
© 2021. Pleiades Publishing, Ltd.
Références
Brikenshtein, V.Kh., Pitina, L.R., Barenboim, G.M., et al., Stereochemistry and kinetics of interaction with DNA of the antitumor antibiotic olivomycin, Mol. Biol., 1984, vol. 18, no. 4, pp. 1606–1616.
Lombó, F., Menéndez, N., Salas, J.A., et al., The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives, Appl. Microbiol. Biotechnol., 2006, vol. 73, no. 1, pp. 1–14.
doi: 10.1007/s00253-006-0511-6
Sabín, J.G. and Morís, F., Exploring novel opportunities for aureolic acids as anticancer drugs, Biochem. Pharmacol.: Open Access, 2013, vol. 2, no. 1, pp. 1–3.
doi: 10.4172/2167-0501.1000e140
Beniaminov, A.D., Chashchina, G.V., Livshits, M.A., et al., Discrimination between G/C binding sites by olivomycin a is determined by kinetics of the drug-dna interaction, Int. J. Mol. Sci., 2020, vol. 21, no. 15, p. 5299.
doi: 10.3390/ijms21155299
Tevyashova, A.N., Shtil, A.A., Olsufyeva, E.N., et al., Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics, Bioorg. Med. Chem., 2011, vol. 19, no. 24, pp. 7387–7393.
doi: 10.1016/j.bmc.2011.10.055
Samusenko, A.V., Mechanisms of cell death under the action of olivomycin and its derivatives, Cand. Sci. (Med.) Dissertation, Moscow, 2009.
Isagulieva, A.K., Beniaminov, A.D., Tatarskiy, V.V., et al., Targeting gene transcription: mechanisms of antitumor potency of olivomycin A and its preclinical derivative, FEBS Open Bio, 2019, vol. 9, no. S1, p. 153.
Vita, M. and Henriksson, M., The Myc oncoprotein as a therapeutic target for human cancer, Semin. Cancer Biol., 2006, vol. 16, no. 4, pp. 318–330.
doi: 10.1016/j.semcancer.2006.07.015
Mognol, G.P., de Araujo-Souza, P.S., Robbs, B.K., et al., Transcriptional regulation of the c-Myc promoter by NFAT1 involves negative and positive NFAT-responsive elements, Cell Cycle, 2012, vol. 11, no. 5, pp. 1014–1028.
doi: 10.4161/cc.11.5.19518
Previdi, S., Malek, A., Albertini, V., et al., Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts, Gynecol. Oncol., 2010, vol. 118, no. 2, pp. 182–188.
doi: 10.1016/j.ygyno.2010.03.020
Sleiman, S.F., Langley, B.C., Basso, M., et al., Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration, J. Neurosci., 2011, vol. 31, no. 18, pp. 6858–6870.
doi: 10.1523/JNEUROSCI.0710-11.2011
Choi, E.-S., Nam, J.-S., Jung, J.-Y., et al., Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer, Sci. Rep., 2014, vol. 4, no. 1, pp. 1–8.